$2.44
0.09[3.83%]
At close: Apr 19
$2.38
-0.0600[-2.46%]
After Hours: 8:26AM EDT
Innate Pharma
(NASDAQ:IPHA)Latest News for Innate Pharma Stock (NASDAQ:IPHA)
Innate Pharma Stock (NASDAQ: IPHA)
Categories: All
Monday, April 15, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Friday, April 05, 2024
Wednesday, April 03, 2024
Monday, April 01, 2024
Friday, March 22, 2024
Thursday, March 21, 2024
Monday, March 11, 2024
Wednesday, March 06, 2024
- Innate Pharma Announces That It Will Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data At AACR 2024Benzinga Newsdesk - Mar 6, 2024, 3:01AM
- Innate Pharma's First Patient Dosed In Phase 1/2 Study Of IPH6501 In Relapsed /Refractory B-Cell Non-Hodgkin's LymphomaBenzinga Newsdesk - Mar 6, 2024, 2:59AM
Tuesday, February 06, 2024
Thursday, January 04, 2024
Wednesday, December 20, 2023
Tuesday, December 19, 2023
Monday, December 18, 2023
Monday, December 11, 2023
- Reported On Sunday, Innate Pharma To Present Results From TELLOMAK Phase 2 Study With Lacutamab In Patients With Sézary Syndrome At ASH 2023Benzinga Newsdesk - Dec 11, 2023, 3:21AM
- Innate Pharma Shares Efficacy And Safety Phase 1 /2 Results Of NK Cell Engager SAR443579 / IPH6101 Developed By Sanofi At ASH 2023Benzinga Newsdesk - Dec 11, 2023, 3:19AM
Wednesday, November 15, 2023
Tuesday, November 14, 2023
Friday, November 03, 2023
Thursday, October 05, 2023
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Oct 5, 2023, 9:10AM
- Regulatory Hurdle For Innate Pharma's Blood Cancer StudiesVandana Singh - Oct 5, 2023, 8:19AM
- Innate Pharma's Lacutamab IND Trials On Partial Hold By FDA After Severe Adverse Reaction; Phase 2 TELLOMAK Final Data Expected Q4 2023Benzinga Newsdesk - Oct 5, 2023, 2:40AM
Friday, September 22, 2023
Monday, September 18, 2023
Thursday, September 14, 2023
Friday, June 16, 2023
- HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price TargetBenzinga Newsdesk - Jun 16, 2023, 6:59AM
- Innate Pharma Says That Interim Efficacy Results From TELLOMAK Phase 2 Study In Advanced Mycosis Fungoides, According To Updated Lymph Node Classification, Confirm Clinical Activity And Favorable Safety Profile Of Lacutamab, Shows Updated ORR Of 42.9%Benzinga Newsdesk - Jun 16, 2023, 4:32AM
Thursday, June 08, 2023
Wednesday, May 10, 2023
Thursday, April 27, 2023
Wednesday, April 19, 2023
Monday, April 03, 2023
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Apr 3, 2023, 9:06AM
- Innate Pharma Has Granted Takeda Exclusive Worldwide Rights To Research And Develop Antibody-drug Conjugates Against An Undisclosed Target, With A Primary Focus On Celiac Disease; Innate will receive an Upfront Of $5M And $410M In Milestone PaymentsBenzinga Newsdesk - Apr 3, 2023, 4:12AM
Friday, March 24, 2023
Thursday, March 23, 2023
Tuesday, February 14, 2023
Wednesday, January 25, 2023
Tuesday, December 27, 2022
- Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Dec 27, 2022, 1:27PM
- US Stocks Open Lower; Nasdaq Slides Over 100 PointsLisa Levin - Dec 27, 2022, 10:21AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Dec 27, 2022, 8:07AM
Monday, December 19, 2022
- Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day SessionLisa Levin - Dec 19, 2022, 1:38PM
- Innate Pharma shares are trading higher after the company and Sanofi announced an expansion of their collaboration for natural killer cell therapeutics in oncology. Innate will receive a €25 million upfront payment.Benzinga Newsdesk - Dec 19, 2022, 8:47AM